CN100365127C - 具有遍在染色质开放表达元件(ucoe)的聚核苷酸 - Google Patents

具有遍在染色质开放表达元件(ucoe)的聚核苷酸 Download PDF

Info

Publication number
CN100365127C
CN100365127C CNB998111554A CN99811155A CN100365127C CN 100365127 C CN100365127 C CN 100365127C CN B998111554 A CNB998111554 A CN B998111554A CN 99811155 A CN99811155 A CN 99811155A CN 100365127 C CN100365127 C CN 100365127C
Authority
CN
China
Prior art keywords
gene
expression
cell
sequence
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB998111554A
Other languages
English (en)
Chinese (zh)
Other versions
CN1334878A (zh
Inventor
迈克尔·安东尼乌
罗伯特·克龙比
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EMD Millipore Corp
Original Assignee
Cobra Therapeutics Ltd
Millipore Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9815879.3A external-priority patent/GB9815879D0/en
Priority claimed from GBGB9906712.6A external-priority patent/GB9906712D0/en
Priority claimed from GBGB9909494.8A external-priority patent/GB9909494D0/en
Application filed by Cobra Therapeutics Ltd, Millipore Corp filed Critical Cobra Therapeutics Ltd
Publication of CN1334878A publication Critical patent/CN1334878A/zh
Application granted granted Critical
Publication of CN100365127C publication Critical patent/CN100365127C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/108Plasmid DNA episomal vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/008Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/20Vector systems having a special element relevant for transcription transcription of more than one cistron
    • C12N2830/205Vector systems having a special element relevant for transcription transcription of more than one cistron bidirectional
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/42Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/46Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/80Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85Vector systems having a special element relevant for transcription from vertebrates mammalian
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/20Vectors comprising a special translation-regulating system translation of more than one cistron
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/20Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/44Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CNB998111554A 1998-07-21 1999-07-21 具有遍在染色质开放表达元件(ucoe)的聚核苷酸 Expired - Lifetime CN100365127C (zh)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
GB9815879.3 1998-07-21
GBGB9815879.3A GB9815879D0 (en) 1998-07-21 1998-07-21 A polynucleotide
US10768898P 1998-11-09 1998-11-09
US60/107,688 1998-11-09
GB9906712.6 1999-03-23
GBGB9906712.6A GB9906712D0 (en) 1999-03-23 1999-03-23 A polynucleotide
US12741099P 1999-04-01 1999-04-01
US60/127,410 1999-04-01
GB9909494.8 1999-04-23
GBGB9909494.8A GB9909494D0 (en) 1999-04-23 1999-04-23 A plasmid
US13401699P 1999-05-12 1999-05-12
US60/134,016 1999-05-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2007101933472A Division CN101260384A (zh) 1998-07-21 1999-07-21 具有遍在染色质开放表达元件(ucoe)的聚核苷酸

Publications (2)

Publication Number Publication Date
CN1334878A CN1334878A (zh) 2002-02-06
CN100365127C true CN100365127C (zh) 2008-01-30

Family

ID=27547316

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998111554A Expired - Lifetime CN100365127C (zh) 1998-07-21 1999-07-21 具有遍在染色质开放表达元件(ucoe)的聚核苷酸

Country Status (8)

Country Link
EP (2) EP1098986B1 (https=)
JP (4) JP4220673B2 (https=)
KR (3) KR100795626B1 (https=)
CN (1) CN100365127C (https=)
AU (1) AU771111B2 (https=)
CA (1) CA2333852C (https=)
MX (1) MXPA01000830A (https=)
WO (1) WO2000005393A2 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100996016B1 (ko) 2000-09-20 2010-11-22 밀리포어 코포레이션 폴리뉴클레오티드
DK1395669T3 (da) 2001-01-26 2009-11-16 Selexis Sa Matriks bindingsregioner og fremgangsmåder til anvendelse af disse
ES2387951T3 (es) * 2001-04-05 2012-10-04 Emd Millipore Corporation Expresión génica mejorada
JP2005500019A (ja) * 2001-04-05 2005-01-06 エムエル ラボラトリーズ ピーエルシー 改良された遺伝子発現
US7812148B2 (en) 2001-04-05 2010-10-12 Millipore Corporation Vectors comprising CpG islands without position effect varigation and having increased expression
HUP0402659A3 (en) 2001-05-30 2008-07-28 Glaxo Group Ltd Chromosome-based platforms
KR20040032105A (ko) * 2001-06-04 2004-04-14 엠엘 래보러토리즈 피엘씨 재조합 단백질의 조성물 및 재조합 단백질의 고수준대규모 생산방법
PT1600510E (pt) 2001-07-04 2007-06-25 Chromagenics Bv Sequências de adn com actividade anti-repressora.
DE60329366D1 (de) 2002-01-09 2009-11-05 Univ Erasmus Medical Ct Induktierbare transposition beim transgenen organismus mit transposon-vektor
CA2489475C (en) 2002-06-14 2011-03-29 Chromagenics B.V. A method for simultaneous production of multiple proteins; vectors and cells for use therein
WO2003106674A2 (en) 2002-06-14 2003-12-24 Chromagenics B.V. Means and methods for regulating gene expression
ATE524559T1 (de) 2002-12-18 2011-09-15 Chromagenics Bv Methode zur verbesserung der proteinproduktion
ATE354645T1 (de) 2002-12-20 2007-03-15 Chromagenics Bv Mittel und methoden zur produktion eines proteins durch chromatin-öffner, die chromatin zugänglicher für transkriptionsfaktoren machen können
US9057079B2 (en) 2003-02-01 2015-06-16 Emd Millipore Corporation Expression elements
KR101269656B1 (ko) 2003-10-24 2013-05-30 셀렉시스 에스. 에이. Mar 서열의 복합 트랜스펙션 방법에 의한 포유동물 세포에서의 고효율 유전자 전달 및 발현
WO2005065348A2 (en) 2003-12-31 2005-07-21 Kalobios, Inc. Transactivation system for mammalian cells
EA014182B1 (ru) 2004-07-20 2010-10-29 Симфоген А/С КОМПОЗИЦИЯ ПОЛИКЛОНАЛЬНЫХ АНТИ-RhD АНТИТЕЛ, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ КОМПОЗИЦИИ
US20060195935A1 (en) 2004-11-08 2006-08-31 Chromagenics B.V. Selection of host cells expressing protein at high levels
US8039230B2 (en) 2004-11-08 2011-10-18 Chromagenics B.V. Selection of host cells expressing protein at high levels
US8999667B2 (en) 2004-11-08 2015-04-07 Chromagenics B.V. Selection of host cells expressing protein at high levels
KR101271884B1 (ko) 2004-11-08 2013-06-05 크로마제닉스 비.브이. 고수준으로 단백질을 발현하는 숙주세포의 선택
ES2384391T3 (es) 2004-11-08 2012-07-04 Chromagenics B.V. Selección de células hospedantes que expresan proteína a altos niveles
GB0504587D0 (en) 2005-03-05 2005-04-13 Ml Lab Plc Vectors comprising guinea pig CMV regulatory elements
GB0509965D0 (en) 2005-05-17 2005-06-22 Ml Lab Plc Improved expression elements
WO2007081336A1 (en) * 2006-01-13 2007-07-19 Five Prime Therapeutics, Inc. Mammalian vectors for high-level expression of recombinant proteins
US7968700B2 (en) 2006-03-20 2011-06-28 Chromagenics B.V. Expression augmenting DNA fragments, use thereof, and methods for finding thereof
JP2010525789A (ja) * 2007-01-08 2010-07-29 ミリポア・コーポレイション 1つ又はそれ以上のきょう雑物の低下したレベルの存在下で組換えタンパク質を生産するための細胞培養法
CN104531699B (zh) * 2014-10-09 2017-03-15 河南农业大学 一种增强外源基因表达的猪的ucoe调控元件片段
AU2015367290A1 (en) * 2014-12-16 2017-05-11 Garvan Institute Of Medical Research Sequencing controls
EP3601542A4 (en) * 2017-03-19 2021-01-13 Applied Stemcell, Inc. NEW INTEGRATION SITES AND THEIR USES
CA3056796A1 (en) 2017-04-03 2018-10-11 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for multiplexed quantitative analysis of cell lineages
US20200385754A1 (en) * 2017-12-07 2020-12-10 Integrity Biosolutions, Llc Engineered ubiquitous chromatin opening elements and uses thereof
US11781146B2 (en) * 2018-05-24 2023-10-10 National University Corporation Hokkaido University Vector including a translation-impaired dihydrofolate reductase gene cassette and ubiquitously acting chromatin opening element
SG11202100765UA (en) 2018-08-15 2021-03-30 Illumina Inc Compositions and methods for improving library enrichment
GB2592776B (en) * 2018-10-02 2023-08-16 Univ Leland Stanford Junior Compositions and methods for multiplexed quantitative analysis of cell lineages
WO2020223160A1 (en) * 2019-04-30 2020-11-05 Chan Zuckerberg Biohub, Inc. A novel chromatin-opening element for stable long term gene expression
CN112575031B (zh) * 2019-09-29 2023-04-07 新乡医学院 一种遍在染色质开放表达元件、重组表达载体、表达系统及其制备方法、应用
CN116574735B (zh) * 2023-07-03 2023-11-10 艾米能斯(苏州)生物科技有限公司 一种多核苷酸及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
GB8718779D0 (en) 1987-08-07 1987-09-16 Grosveld F G Dna sequence & expression vector
EP0945515A3 (en) 1989-11-06 2002-08-21 Cell Genesys, Inc. Production of proteins using homologous recombination
EP0532525B1 (de) 1990-05-18 1995-08-16 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Neue protein-polykation-konjugate
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
GB9109928D0 (en) 1991-05-08 1991-07-03 Interox Chemicals Ltd Thickened compositions
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
CA2131620A1 (en) 1992-03-20 1993-09-30 Louis C. Smith A dna transporter system and method of use
US5583009A (en) 1992-12-08 1996-12-10 University Of Washington Method of preparing recombinant proteins in transgenic animals containing metallothionein gene elements that bestow tissue-independent copy number-dependent, position-indepedent gene expression
US5578475A (en) 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
EP0831922A2 (en) 1995-06-08 1998-04-01 Therexsys Limited Improved pharmaceutical compositions for gene therapy
JP2000516472A (ja) 1996-08-16 2000-12-12 メディカル リサーチ カウンシル 組織特異的遺伝子発現を与える自己複製型エピソーム性発現ベクター
DE19651443A1 (de) * 1996-12-11 1998-06-18 Hoechst Ag Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme
AU749113B2 (en) 1997-02-12 2002-06-20 Innovata Plc Compositions and methods for highly efficient transfection

Also Published As

Publication number Publication date
JP2009102331A (ja) 2009-05-14
KR100795626B1 (ko) 2008-01-17
EP1098986A2 (en) 2001-05-16
EP1098986B1 (en) 2011-12-28
AU5053499A (en) 2000-02-14
CA2333852A1 (en) 2000-02-03
KR20010083131A (ko) 2001-08-31
JP2008109931A (ja) 2008-05-15
WO2000005393A3 (en) 2000-08-17
CN1334878A (zh) 2002-02-06
WO2000005393A2 (en) 2000-02-03
JP2002522027A (ja) 2002-07-23
HK1035740A1 (en) 2001-12-07
JP4220673B2 (ja) 2009-02-04
EP2348118A1 (en) 2011-07-27
JP2005052149A (ja) 2005-03-03
KR20070108336A (ko) 2007-11-09
AU771111B2 (en) 2004-03-11
CA2333852C (en) 2007-05-29
KR20090117675A (ko) 2009-11-12
MXPA01000830A (es) 2002-06-04

Similar Documents

Publication Publication Date Title
CN100365127C (zh) 具有遍在染色质开放表达元件(ucoe)的聚核苷酸
US8058028B2 (en) Polynucleotide
US20040019923A1 (en) Exogenous proteins expressed in avians and their eggs
US20040019922A1 (en) Exogenous proteins expressed in avians and their eggs
US20070130629A1 (en) Renal Regulatory Elements and Methods of Use Thereof
CN101260384A (zh) 具有遍在染色质开放表达元件(ucoe)的聚核苷酸
US20020016974A1 (en) Transgenic, non-human animals containing a coxsackie/adenovirus receptor (CAR)
AU2001269862B2 (en) Renal regulatory elements and methods of use thereof
Podetz-Pedersen et al. 232. Ex Vivo Lentiviral Transduction of the Human Purine Nucleoside Phosphorylase (PNP) Gene in Bone Marrow Derived Hematopoietic Stem Cells: An In Vivo Model of Gene Therapy for PNP Deficient T-Cell Immunodeficiency
AU2001269862A1 (en) Renal regulatory elements and methods of use thereof

Legal Events

Date Code Title Description
C06 Publication
C10 Entry into substantive examination
PB01 Publication
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: ML LABORATORIES PLC

Free format text: FORMER OWNER: COBRA THERAPEUTICS LTD.

Effective date: 20031015

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20031015

Address after: London, England

Applicant after: ML LABORATORIES PLC

Address before: Mount Hood

Applicant before: Cobra Therapeutics Ltd.

ASS Succession or assignment of patent right

Owner name: SERUM INVESTMENT CO.,LTD.

Free format text: FORMER OWNER: INNOVATA PLC

Effective date: 20060714

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20060714

Address after: Delaware

Applicant after: Serum investment Co.

Address before: British Nottingham

Applicant before: Innovation Public Ltd.

ASS Succession or assignment of patent right

Owner name: MIANYANG FUTE RELAY CO., LTD.

Free format text: FORMER OWNER: BLOOD SERUM CO.,LTD.

Effective date: 20070720

Owner name: SERUM FINANCE CO.,LTD.

Free format text: FORMER OWNER: SERUM ROYAL CO.,LTD.

Effective date: 20070720

Owner name: SERUM ROYAL CO.,LTD.

Free format text: FORMER OWNER: SERUM INVESTMENT CO.,LTD.

Effective date: 20070720

Owner name: BLOOD SERUM CO.,LTD.

Free format text: FORMER OWNER: SERUM FINANCE CO.,LTD.

Effective date: 20070720

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20070720

Address after: American Georgia

Applicant after: Serum company

Address before: Bahamian archipelago bus Island

Applicant before: Serum finance Co.

Effective date of registration: 20070720

Address after: Bahamian archipelago bus Island

Applicant after: Serum finance Co.

Address before: Bahamian archipelago bus Island

Applicant before: Serum Company RoyaL

Effective date of registration: 20070720

Address after: Bahamian archipelago bus Island

Applicant after: Serum Company RoyaL

Address before: Delaware

Applicant before: Serum investment Co.

Effective date of registration: 20070720

Address after: Massachusetts, USA

Applicant after: Millipore Corp.

Address before: American Georgia

Applicant before: Serum company

C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: EMD MILLIPORE CORPORATION

Free format text: FORMER NAME: MILLIPORE CORP.

CP01 Change in the name or title of a patent holder

Address after: Massachusetts, USA

Patentee after: EMD MILLIPORE Corp.

Address before: Massachusetts, USA

Patentee before: Millipore Corp.

CX01 Expiry of patent term

Granted publication date: 20080130

CX01 Expiry of patent term